MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 2 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mainor, Candace
OXEL, NCT03487666: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

Active, not recruiting
2
45
US
Nivolumab, Opdivo, Capecitabine, Xeloda
Georgetown University, Bristol-Myers Squibb
Triple Negative Breast Cancer
11/21
12/22
WI223281, NCT03535506: Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery

Terminated
2
17
US
Palbociclib, Ibrance
Georgetown University, Pfizer
DCIS
12/23
12/23
NCT03941730: Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Enrolling by invitation
2
38
US
Biopsy, BIOPSY_TYPE, Bx, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Therapeutic Estradiol, 17 Beta-Estradiol, Aquadiol, Climara, Dimenformon, Diogyn, Diogynets, Estrace, ESTRADIOL, Estraldine, Oestradiol, Ovocylin, Progynon, Vagifem
Mayo Clinic, National Cancer Institute (NCI)
Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma
07/26
07/26
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Recruiting
2
197
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research
Breast Cancer, Triple Negative Breast Cancer
01/29
01/34
RAGE, NCT05256745: Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

Recruiting
1/2
48
US
TTP488, Azeliragon, ddAC/ddT, Dose dense doxorubicin plus cyclophosphamide, dose dense paclitaxel, TC, Docetaxel plus cyclophosphamide, TCHP, Docetaxel, carboplatin, trastuzumab, and pertuzumab, Chemotherapy regimen that includes ddAC, Dose dense doxorubicin plus cyclophosphamide
Georgetown University
Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
11/24
11/24
NCT03586297: Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

Recruiting
N/A
49
US
Hackensack Meridian Health, Breast Cancer Research Foundation
Triple Negative Breast Cancer
01/25
01/25
Ashai, Nadia
OASIS, NCT04720664: Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

Terminated
2
11
US
SM-88
Georgetown University, Tyme, Inc
Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma
02/23
02/23
Bouker, Kerrie
LEANORA, NCT04657679: Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts

Terminated
4
21
US
Ribociclib, KISQALI
Georgetown University, Medstar Health Research Institute, Breast Cancer Research Foundation, Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS)
Breast Cancer
10/23
10/23
Bouker, Kerri
No trials found
Aguila, Frankie
No trials found

Download Options